All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
5.1 Antibacterial drugs
Toggle Pages
5.1.1 Penicillins
5.1.2 Cephalosporins, carbapenems, and other beta-lactams
5.1.3 Tetracyclines
5.1.4 Aminoglycosides
5.1.5 Macrolides
5.1.6 Clindamycin
5.1.7 Some other antibacterials
5.1.8 Sulfonamides and trimethoprim
5.1.10 Antileprotic drugs
5.1.11 Metronidazole and tinidazole
5.1.12 Quinolones
5.1.13 Urinary-tract infections
Chapter 5: Infections
Toggle Parent Pages
Print this page
Principles of antibacterial treatment
Upper respiratory tract infections
Lower respiratory tract infections
Acute exacerbation of bronchiectasis (non-cystic fibrosis)
Urinary tract infections (UTI)
Gastro-intestinal tract infections
Genital tract infections
Meningitis
Skin and soft tissue infections
Lyme disease
Eye infections
Oral and dental infections
COVID-19 treatments for patients who do not require hospitalisation
5.1 Antibacterial drugs
5.2 Antifungal drugs
5.3 Antiviral drugs
5.4 Antiprotozoal drugs
5.5 Anthelmintics
Contact us about this page
5.1.4 Aminoglycosides
First Line
Second Line
Specialist
Hospital Only
Tobramycin
- Inhalation powder capsules with device 28mg
Notes
- NICE TA276: Tobramycin dry powder for inhalation (DPI) (TOBI Podhaler) is recommended as an option for treating chronic pulmonary infection caused by Pseudomonas aeruginosa in people with cystic fibrosis (March 2013), only if:
- nebulised tobramycin is considered an appropriate treatment, that is, when colistimethate sodium is contraindicated, is not tolerated or has not produced an adequate clinical response, and
- the manufacturer provides it with the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.
